Vertex Pharmaceuticals 통합
US ˙ NasdaqGS ˙ US92532F1003

SecurityVRTX / Vertex Pharmaceuticals Incorporated
InstitutionMorse Asset Management, Inc
Latest Disclosed Ownership10,565 shares
Latest Disclosed Value $ 4,717,695
Morse Asset Management, Inc reports 1.36% increase in ownership of VRTX / Vertex Pharmaceuticals Incorporated

On May 14, 2026 - Morse Asset Management, Inc filed a 13F-HR form disclosing ownership of 10,565 shares of Vertex Pharmaceuticals Incorporated (US:VRTX) valued at $4,717,695 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 3, 2026 disclosing 10,423 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of 1.36% during the quarter. The current value of the position is $4,720,759 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-14 2026-03-31 13F VERTEX PHARMACEUTICALS INC COM Stock 92532F100 10,565 142 1.36 4,718 -0.17 0.9806
2026-02-03 2025-12-31 13F VERTEX PHARMACEUTICALS INC COM Stock 92532F100 10,423 118 1.15 4,725 17.10 0.9445
2025-11-14 2025-09-30 13F VERTEX PHARMACEUTICALS INC COM Stock 92532F100 10,305 18 0.17 4,036 -11.88 0.8054
2025-08-15 2025-06-30 13F VERTEX PHARMACEUTICALS INC COM Stock 92532F100 10,287 -174 -1.66 4,580 -9.70 1.0035
2025-05-05 2025-03-31 13F VERTEX PHARMACEUTICALS INC COM Stock 92532F100 10,461 -94 -0.89 5,072 19.32 1.2802
2025-02-14 2024-12-31 13F VERTEX PHARMACEUTICALS INC COM Stock 92532F100 10,555 578 5.79 4,250 -8.41 0.9710
2024-11-20 2024-09-30 13F/A-1 VERTEX PHARMACEUTICALS INC COM Stock 92532F100 9,977 -138 -1.36 4,640 115,900.00 1.0015
2024-11-14 2024-09-30 13F VERTEX PHARMACEUTICALS INC COM Stock 92532F100 10,003 -112 5 1.0020
2024-08-14 2024-06-30 13F Vertex Pharmaceuticals COM 92532F100 10,115 -80 -0.78 5 0.00 1.1497
2024-05-15 2024-03-31 13F Vertex Pharmaceuticals COM 92532F100 10,195 706 7.44 4 33.33 1.0875
2024-02-15 2023-12-31 13F Vertex Pharmaceuticals COM 92532F100 9,489 1,547 19.48 4 50.00 1.1365
2023-11-13 2023-09-30 13F Vertex Pharmaceuticals COM 92532F100 7,942 621 8.48 3 0.00 0.8738
2023-08-14 2023-06-30 13F Vertex Pharmaceuticals COM 92532F100 7,321 1,425 24.17 3 100.00 0.7834
2023-05-03 2023-03-31 13F Vertex Pharmaceuticals COM 92532F100 5,896 681 13.06 2 0.00 0.6278
2023-02-08 2022-12-31 13F Vertex Pharmaceuticals COM 92532F100 5,215 1,278 32.46 2 -99.91 0.5470
2022-11-14 2022-09-30 13F Vertex Pharmaceuticals COM 92532F100 3,937 2,105 114.90 1,140 120.93 0.4304
2022-08-11 2022-06-30 13F Vertex Pharmaceuticals COM 92532F100 1,832 375 25.74 516 35.79 0.1656
2022-05-12 2022-03-31 13F Vertex Pharmaceuticals COM 92532F100 1,457 1,457 380 0.0945
2021-05-13 2021-03-31 13F/A-1 Vertex Pharmaceuticals COM 92532F100 0 -1,268 -100.00 0 -100.00
2021-02-11 2020-12-31 13F Vertex Pharmaceuticals COM 92532F100 1,268 -9,710 -88.45 300 -89.96 0.0832
2020-11-09 2020-09-30 13F Vertex Pharmaceuticals COM 92532F100 10,978 2,411 28.14 2,987 20.10 0.9577
2020-08-14 2020-06-30 13F Vertex Pharmaceuticals COM 92532F100 8,567 4,837 129.68 2,487 180.07 0.8859
2020-05-01 2020-03-31 13F Vertex Pharmaceuticals COM 92532F100 3,730 2,419 184.52 888 209.41 0.4240
2020-01-31 2019-12-31 13F Vertex Pharmaceuticals COM 92532F100 1,311 1,311 287 0.0984
2019-11-05 2019-09-30 13F Vertex Pharmaceuticals COM 92532F100 0 -9,628 -100.00 0 -100.00
2019-08-01 2019-06-30 13F Vertex Pharmaceuticals COM 92532F100 9,628 -2,880 -23.03 1,766 -23.25 0.5201
2019-05-02 2019-03-31 13F Vertex Pharmaceuticals COM 92532F100 12,508 6,795 118.94 2,301 142.98 0.6898
2019-02-13 2018-12-31 13F Vertex Pharmaceuticals COM 92532F100 5,713 -10,102 -63.88 947 -68.93 0.3363
2018-11-01 2018-09-30 13F Vertex Pharmaceuticals COM 92532F100 15,815 9,764 161.36 3,048 196.50 0.8032
2018-08-15 2018-06-30 13F Vertex Pharmaceuticals COM 92532F100 6,051 675 12.56 1,028 17.35 0.2817
2018-05-02 2018-03-31 13F Vertex Pharmaceuticals COM 92532F100 5,376 46 0.86 876 9.64 0.2426
2018-01-29 2017-12-31 13F Vertex Pharmaceuticals COM 92532F100 5,330 180 3.50 799 2.04 0.2223
2017-10-31 2017-09-30 13F Vertex Pharmaceuticals COM 92532F100 5,150 5,150 783 0.2333
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.